New Agreement Expands Existing Preclinical Collaborations
Hemispherx Biopharma, Inc. (NYSE American: HEB) announces
the signing of a clinical trial agreement with Roswell Park
Comprehensive Cancer Center to evaluate Ampligen in combination with
checkpoint inhibitors (CPIs). The Phase IIa clinical trial will evaluate
the immune-mediated effects of cytokine modulation in combination with
CPIs in patients with primary resistance to CPI therapy. The protocol
will seek to evaluate the combination of Ampligen and CPIs in patients
with advanced urothelial carcinoma, renal cell carcinoma and melanoma.
Ampligen is the Company’s investigational immune-enhancing TLR3 agonist
that has demonstrated a robust anti-cancer effect in preclinical models
when combined with CPIs. This new agreement expands the extensive prior
clinical and preclinical work into the clinical checkpoint blockade
arena and offers the opportunity to begin evaluation of this combination
therapy in patients with a variety of solid tumors where large numbers
of patients do not respond or progress following treatment with standard
CPI-based therapy.
“This event marks an important milestone for Hemispherx as we evaluate Ampligen in combination with CPIs in difficult-to-treat solid tumors and among a patient population that is largely relapsed and/or refractory to treatment,” said Thomas K. Equels, Chief Executive Officer of Hemispherx. “Our expanded collaboration with Roswell Park offers an ideal setting for these early stage trials. We have developed a productive working relationship with this world-class team and look forward to beginning these important clinical trials.”
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology. Hemispherx's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and a clinical trial, Hemispherx believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® already conducted by Hemispherx include studies of the potential treatment of cancer patients with renal cell carcinoma and malignant melanoma. These and other potential uses will require additional clinical trials to generate the safety and effectiveness data necessary to support regulatory approval. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.
About Roswell Park Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.
No comments:
Post a Comment